Deucravacitinib
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Deucravacitinib
- DrugBank Accession Number
- DB16650
- Background
Deucravacitinib is under investigation in clinical trial NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Deucravacitinib (DB16650)
- Weight
- Average: 425.467
Monoisotopic: 425.200316838 - Chemical Formula
- C20H22N8O3
- Synonyms
- Deucravacitinib
- External IDs
- BMS-986165
- WHO 11342
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Deucravacitinib hydrochloride 95C5558CF4 1609392-28-0 LILQGPVDQZORJG-NIIDSAIPSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- N0A21N6RAU
- CAS number
- 1609392-27-9
- InChI Key
- BZZKEPGENYLQSC-FIBGUPNXSA-N
- InChI
- InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3
- IUPAC Name
- 6-cyclopropaneamido-4-{[2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide
- SMILES
- [2H]C([2H])([2H])NC(=O)C1=C(NC2=CC=CC(C3=NN(C)C=N3)=C2OC)C=C(NC(=O)C2CC2)N=N1
References
- General References
- Not Available
- External Links
- ChemSpider
- 72380005
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Psoriasis 1 3 Completed Treatment Psoriasis 2 3 Not Yet Recruiting Treatment Psoriatic Arthritis 2 3 Recruiting Treatment Psoriasis 2 3 Recruiting Treatment Psoriasis Vulgaris (Plaque Psoriasis) 1 2 Active Not Recruiting Treatment Systemic Lupus Erythematosus (SLE) 1 2 Completed Treatment Psoriasis 1 2 Completed Treatment Psoriatic arthritis aggravated 1 2 Not Yet Recruiting Treatment Crohn's Disease (CD) / Ulcerative Colitis 1 2 Not Yet Recruiting Treatment Discoid Lupus Erythematosus (DLE) / Lupus Erythematosus, Subacute Cutaneous 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.159 mg/mL ALOGPS logP 1.8 ALOGPS logP 2.1 ChemAxon logS -3.4 ALOGPS pKa (Strongest Acidic) 11.09 ChemAxon pKa (Strongest Basic) 2.38 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 135.95 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 138.38 m3·mol-1 ChemAxon Polarizability 44.49 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on March 24, 2021 22:54 / Updated on March 26, 2021 04:01